Palvella Therapeutics (PVLA) Current Assets (2013 - 2026)

Palvella Therapeutics (PVLA) has reported Current Assets for 14 consecutive years, with $263.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 231.36% year-over-year to $263.2 million; the TTM figure through Mar 2026 stood at $263.2 million (up 231.36% YoY), while the FY2025 annual figure was $59.0 million, down 33.15% from the prior year.
• Current Assets grew to $263.2 million in Q1 2026 per PVLA's latest filing, from $59.0 million in the prior quarter.
• Across five years, Current Assets topped out at $263.2 million in Q1 2026 and bottomed at $7.5 million in Q4 2023.
• Historically, Current Assets has averaged $84.2 million across 5 years, with a median of $73.6 million in 2022.
• Annual changes were most pronounced in 2023 — Current Assets tumbled 89.72% — and 2024, when it surged 1068.97%.
• Palvella Therapeutics' Current Assets stood at $73.4 million in 2022, then sank by 89.72% to $7.5 million in 2023, then soared by 1068.97% to $88.2 million in 2024, then sank by 33.15% to $59.0 million in 2025, then jumped by 346.25% to $263.2 million in 2026.
• Business Quant data shows PVLA's Current Assets at $263.2 million in Q1 2026, $59.0 million in Q4 2025, and $66.9 million in Q3 2025.